Description
Indication & Scope
XinKeQing® Higenamine Hydrochloride Injection is used as a pharmacological stress agent for cardiac function stress imaging examinations, to induce controlled cardiac load and assist diagnosis of myocardial ischemia lesions during nuclear medicine or ultrasound cardiac scans.
- Mechanism: Higenamine hydrochloride is a selective beta-adrenergic receptor partial agonist. Continuous intravenous infusion activates cardiac β1 receptors to accelerate heart rate, raise myocardial contractility and increase myocardial oxygen demand, simulating physical exercise cardiac load without patient movement. This induced myocardial oxygen supply-demand imbalance can expose hidden ischemic myocardial lesions visible on cardiac imaging equipment.
- Drug class: Cardiac stress diagnostic agent; selective β-adrenoceptor partial agonist injectable.
- Clinical use: Alternative stress substitute for patients unable to complete treadmill exercise cardiac stress tests. It standardizes cardiac load levels during imaging, improves detection sensitivity of mild myocardial ischemia, supports accurate diagnosis of coronary artery disease without physical activity requirements.
| Generic Name | Higenamine Hydrochloride Injection |
| Brand Name | XinKeQing |
| Ingredient | Higenamine Hydrochloride Injection |
| Dosage Form | Injection |
| Package | 2ml: 2.5mg*1 vial/box |
| Conditions Treated | Patients requiring cardiac function stress imaging evaluation who cannot finish standard treadmill exercise stress testing due to physical disabilities, joint disease, severe fatigue or other mobility limitations |
| Taboos | Patients with uncontrolled severe arrhythmia, severe aortic stenosis, unstable acute myocardial infarction, uncontrolled severe hypertension; patients with hypersensitivity to higenamine hydrochloride or injection excipients; pregnant women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Unopened ampoule vials refrigerated at 2°C–8°C, protected from light. Avoid repeated freezing and thawing cycles of the liquid injection |
| Manufacturer | Zhuhai RunDu Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20260017 |
| Approval Date | Mar 31, 2026 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Graded continuous intravenous infusion for 3 minutes at escalating flow rates: 0.5, 1.0, 2.0 and 4.0 μg per kilogram of patient body weight per minute, under real-time ECG monitoring throughout infusion.
Time: Start intravenous infusion of the injection 10 minutes before formal cardiac imaging scanning, maintain graded infusion during the entire image acquisition process.
Instructions for use: Only medical staff with cardiac emergency training can perform infusion and monitoring. Equip emergency anti-arrhythmia and resuscitation drugs on standby during all injection procedures. Monitor blood pressure, heart rate and real-time ECG continuously throughout infusion. Immediately stop infusion if severe palpitations, chest pain or hypotension occurs. Discontinue all beta-blocker heart medicines at least 48 hours before scheduled stress imaging.
Interaction: Concomitant beta-blockers fully neutralize higenamine’s cardiac load-inducing effect and must be paused before examination. Combined anticoagulant medicines slightly raise minor bleeding risk at the intravenous injection puncture site. Anti-hypertensive calcium channel blockers may amplify hypotension side effects during infusion.
Side effects:
1. Common mild transient adverse reactions: palpitations, mild flushing, slight headache, temporary tachycardia, mild chest tightness that resolves quickly after stopping infusion.
2. Severe rare adverse reactions: sustained severe arrhythmia, sharp hypotension, severe angina pectoris attack, acute myocardial ischemia exacerbation.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is Higenamine Hydrochloride Injection used for during heart check-ups?
Higenamine Hydrochloride Injection acts as a medicine-induced heart load substitute for patients who cannot walk on treadmill exercise machines for cardiac ischemia imaging tests.
Who cannot receive this intravenous Higenamine Hydrochloride Injection for cardiac stress imaging at all?
Patients with uncontrolled severe irregular heart rhythm, recent unstable heart attack, untreated high blood pressure or drug allergy to this injection are fully restricted.
Does patients need to stop regular beta-blocker heart pills before Higenamine Hydrochloride Injection cardiac stress scan?
Yes, patients must stop taking beta-blocker heart medications for at least 48 hours before your scheduled imaging appointment, or the injection will not work properly.
What temporary uncomfortable feelings might patients have during the intravenous infusion process of Higenamine Hydrochloride Injection?
Transient fast heartbeat, facial flushing or light mild chest tightness may appear, which will fade rapidly once medical staff stop the infusion pump.
XinKeQing® | Higenamine Hydrochloride Injection | Cardiac Function Assessment | DengYueRX
INN: Higenamine Hydrochloride Injection
Indications: Cardiac function assessment
Dosage Form: Injection
Strength: 2ml: 2.5mg/vial
